BAR-501 is a selective GPBAR1 agonist devoid of any FXR agonistic activity. BAR501 effectively reduced hepatic perfusion pressure and counteracted the vasoconstriction activity of norepinephrine. BAR501 rescues from endothelial dysfunction in rodent models of portal hypertension by exerting genomic and non-genomic effects on CSE, eNOS and ET-1 in liver sinusoidal cells. References: Renga B, Cipriani S, Carino A, Simonetti M, Zampella A, Fiorucci S. Reversal of Endothelial Dysfunction by GPBAR1 Agonism in Portal Hypertension Involves a AKT/FOXOA1 Dependent Regulation of H2S Generation and Endothelin-1. PLoS One. 2015 Nov 5;10(11):e0141082. doi: 10.1371/journal.pone.0141082. eCollection 2015. PubMed PMID: 26539823; PubMed Central PMCID: PMC4634759.

纯度：≥98%

CAS：1632118-69-4